BRIEF-Vir Biotechnology Announces Encouraging Safety And Efficacy Data In Ongoing Dose Escalation Trials For Dual Masked T-Cell Engagers VIR-5818 In Solid Tumors And VIR-5500 In mCRPC

Reuters01-08 20:57

Jan 8 (Reuters) - Vir Biotechnology Inc :

* VIR BIOTECHNOLOGY ANNOUNCES ENCOURAGING SAFETY AND EFFICACY DATA IN ONGOING DOSE ESCALATION TRIALS FOR DUAL MASKED T-CELL ENGAGERS VIR-5818 IN SOLID TUMORS AND VIR-5500 IN MCRPC

* VIR BIOTECHNOLOGY INC - VIR-5818 SHOWS 50% TUMOR SHRINKAGE IN HER2 CANCERS AT ≥400 ΜG/KG

* VIR BIOTECHNOLOGY INC - NO DOSE-LIMITING CRS OBSERVED FOR VIR-5818 OR VIR-5500

* VIR BIOTECHNOLOGY INC: PROMISING SAFETY PROFILE WITH MTD NOT YET REACHED FOR VIR-5818 OR VIR-5500

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501218047?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 20:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501218047","market":"us","top_or_hot":-1,"title":"BRIEF-Vir Biotechnology Announces Encouraging Safety And Efficacy Data In Ongoing Dose Escalation Trials For Dual Masked T-Cell Engagers VIR-5818 In Solid Tumors And VIR-5500 In mCRPC","media":"Reuters","content":"<html><body><p>Jan 8 (Reuters) - Vir Biotechnology Inc   :</p><p>   * VIR BIOTECHNOLOGY ANNOUNCES ENCOURAGING SAFETY AND EFFICACY DATA IN ONGOING DOSE ESCALATION TRIALS FOR DUAL MASKED T-CELL ENGAGERS VIR-5818 IN SOLID TUMORS AND VIR-5500 IN MCRPC</p><p>   * VIR BIOTECHNOLOGY INC - VIR-5818 SHOWS 50% TUMOR SHRINKAGE IN HER2 CANCERS AT ≥400 ΜG/KG</p><p>   * VIR BIOTECHNOLOGY INC - NO DOSE-LIMITING CRS OBSERVED FOR VIR-5818 OR VIR-5500</p><p>   * VIR BIOTECHNOLOGY INC: PROMISING SAFETY PROFILE WITH MTD NOT YET REACHED FOR VIR-5818 OR VIR-5500</p><p>Source text:   Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Vir Biotechnology Announces Encouraging Safety And Efficacy Data In Ongoing Dose Escalation Trials For Dual Masked T-Cell Engagers VIR-5818 In Solid Tumors And VIR-5500 In mCRPC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Vir Biotechnology Announces Encouraging Safety And Efficacy Data In Ongoing Dose Escalation Trials For Dual Masked T-Cell Engagers VIR-5818 In Solid Tumors And VIR-5500 In mCRPC\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-08 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jan 8 (Reuters) - Vir Biotechnology Inc   :   * VIR BIOTECHNOLOGY ANNOUNCES ENCOURAGING SAFETY AND EFFICACY DATA IN ONGOING DOSE ESCALATION TRIALS FOR DUAL MASKED T-CELL ENGAGERS VIR-5818 IN SOLID ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2501218047","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501218047","pubTimestamp":1736341024,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Jan 8  - Vir Biotechnology Inc   :   * VIR BIOTECHNOLOGY ANNOUNCES ENCOURAGING SAFETY AND EFFICACY DATA IN ONGOING DOSE ESCALATION TRIALS FOR DUAL MASKED T-CELL ENGAGERS VIR-5818 IN SOLID TUMORS AND VIR-5500 IN MCRPC   * VIR BIOTECHNOLOGY INC - VIR-5818 SHOWS 50% TUMOR SHRINKAGE IN HER2 CANCERS AT ≥400 ΜG/KG   * VIR BIOTECHNOLOGY INC - NO DOSE-LIMITING CRS OBSERVED FOR VIR-5818 OR VIR-5500   * VIR BIOTECHNOLOGY INC: PROMISING SAFETY PROFILE WITH MTD NOT YET REACHED FOR VIR-5818 OR VIR-5500Source text:   Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","VIR":"Vir Biotechnology, Inc.","BK4535":"淡马锡持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"BRIEF-Vir Biotechnology宣布正在进行的双盲T细胞衔接剂VIR-5818治疗实体瘤和VIR-5500治疗mCRPC的剂量递增试验中令人鼓舞的安全性和有效性数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":1},"content_text":"Jan 8 (Reuters) - Vir Biotechnology Inc   :   * VIR BIOTECHNOLOGY ANNOUNCES ENCOURAGING SAFETY AND EFFICACY DATA IN ONGOING DOSE ESCALATION TRIALS FOR DUAL MASKED T-CELL ENGAGERS VIR-5818 IN SOLID TUMORS AND VIR-5500 IN MCRPC   * VIR BIOTECHNOLOGY INC - VIR-5818 SHOWS 50% TUMOR SHRINKAGE IN HER2 CANCERS AT ≥400 ΜG/KG   * VIR BIOTECHNOLOGY INC - NO DOSE-LIMITING CRS OBSERVED FOR VIR-5818 OR VIR-5500   * VIR BIOTECHNOLOGY INC: PROMISING SAFETY PROFILE WITH MTD NOT YET REACHED FOR VIR-5818 OR VIR-5500Source text:   Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501218047"}